| General Information | |
|---|---|
| ZINC ID | ZINC000036294739 |
| Molecular Weight (Da) | 451 |
| SMILES | Cc1c(C(=O)N[C@@H](C)C(C)C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C22Cl3N3O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 120.383 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 29 |
| LogP | 7.218 |
| Activity (Ki) in nM | 40.738 |
| Polar Surface Area (PSA) | 46.92 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.118 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.27 |
| Ilogp | 4.19 |
| Xlogp3 | 7.18 |
| Wlogp | 6.58 |
| Mlogp | 5.1 |
| Silicos-it log p | 6.26 |
| Consensus log p | 5.86 |
| Esol log s | -7.2 |
| Esol solubility (mg/ml) | 0.0000287 |
| Esol solubility (mol/l) | 6.37E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.99 |
| Ali solubility (mg/ml) | 0.00000464 |
| Ali solubility (mol/l) | 1.03E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.81 |
| Silicos-it solubility (mg/ml) | 0.00000069 |
| Silicos-it solubility (mol/l) | 1.54E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.95 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.69 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.125 |
| Logd | 4.949 |
| Logp | 6.452 |
| F (20%) | 0.001 |
| F (30%) | 0.075 |
| Mdck | - |
| Ppb | 99.54% |
| Vdss | 1.487 |
| Fu | 1.87% |
| Cyp1a2-inh | 0.349 |
| Cyp1a2-sub | 0.824 |
| Cyp2c19-inh | 0.9 |
| Cyp2c19-sub | 0.322 |
| Cl | 4.157 |
| T12 | 0.039 |
| H-ht | 0.313 |
| Dili | 0.965 |
| Roa | 0.259 |
| Fdamdd | 0.676 |
| Skinsen | 0.029 |
| Ec | 0.003 |
| Ei | 0.014 |
| Respiratory | 0.035 |
| Bcf | 3.734 |
| Igc50 | 5.14 |
| Lc50 | 6.255 |
| Lc50dm | 6.186 |
| Nr-ar | 0.004 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.756 |
| Nr-aromatase | 0.852 |
| Nr-er | 0.833 |
| Nr-er-lbd | 0.27 |
| Nr-ppar-gamma | 0.102 |
| Sr-are | 0.892 |
| Sr-atad5 | 0.024 |
| Sr-hse | 0.479 |
| Sr-mmp | 0.918 |
| Sr-p53 | 0.906 |
| Vol | 427.084 |
| Dense | 1.052 |
| Flex | 0.333 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.477 |
| Synth | 2.747 |
| Fsp3 | 0.273 |
| Mce-18 | 42 |
| Natural product-likeness | -1.402 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |